ES2157326T3 - Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea. - Google Patents
Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea.Info
- Publication number
- ES2157326T3 ES2157326T3 ES95916845T ES95916845T ES2157326T3 ES 2157326 T3 ES2157326 T3 ES 2157326T3 ES 95916845 T ES95916845 T ES 95916845T ES 95916845 T ES95916845 T ES 95916845T ES 2157326 T3 ES2157326 T3 ES 2157326T3
- Authority
- ES
- Spain
- Prior art keywords
- apc
- pct
- factor
- cleavage sites
- methods
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
Abstract
ESTA INVENCION SE REFIERE AL DIAGNOSTICO DEL DEFECTO CONGENITO EN EL SISTEMA ANTICOAGULANTE DE LA PROTEINA C. LOS METODOS DESCRITOS ESTAN BASADOS EN LA DETECCION DE MUTACIONES EN LOS SITIOS DE DIVISION DE LOS FACTORES DE COAGULACION QUE ESTAN BAJO CONTROL DE LA PROTEINA C ACTIVADA (APC). PRUEBAS DE DIAGNOSTICO INCLUYEN ANALISIS DE LOS SITIOS DE DIVISION APC DE FACTOR V Y FACTOR VIII, MEDIANTE EL USO DE INICIADORES ESPECIFICOS PARA AMPLIFICAR SELECTIVAMENTE A PARTIR DE ARN, ADNC DERIVADO DE ARN O ADN CROMOSOMAL, PARTES DEL FACTOR V Y FACTOR VIII QUE CONTIENEN SITIOS DE DIVISION PARA APC. SE DESCRIBEN METODOS QUE CONTROLAN LA PRESENCIA DE MUTACIONES EN EL SITIO DE DIVISION DEL APC Y SU UTILIDAD EN EL DIAGNOSTICO DE TRASTORNOS TROMBO-EMBOLICOS.LA INVENCION ADEMAS DESCRIBE METODOS PARA CORREGIR LOS DEFECTOS DETECTADOS DE ACUERDO A LA INVENCION, ASI COMO NUEVOS AGENTES TERAPEUTICOS QUE PUEDEN SER USADOS EN EL TRATAMIENTO DE TRASTORNOS HEMORRAGICOS, DICHOS AGENTES ESTAN BASADOS EN LAS PROTEINAS DE FACTOR V Y FACTOR VIII DEFECTUOSAS QUE PRODUCEN LOS TRASTORNOS TROMBOTICOS DESCRITOS ARRIBA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP94201116 | 1994-04-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2157326T3 true ES2157326T3 (es) | 2001-08-16 |
Family
ID=8216820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES95916845T Expired - Lifetime ES2157326T3 (es) | 1994-04-22 | 1995-04-21 | Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea. |
Country Status (11)
Country | Link |
---|---|
US (1) | US6083905A (es) |
EP (1) | EP0756638B1 (es) |
JP (1) | JP3810080B2 (es) |
AT (1) | ATE200225T1 (es) |
AU (1) | AU697205B2 (es) |
CA (1) | CA2188463C (es) |
DE (1) | DE69520569T2 (es) |
DK (1) | DK0756638T3 (es) |
ES (1) | ES2157326T3 (es) |
GR (1) | GR3036000T3 (es) |
WO (1) | WO1995029259A1 (es) |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100384251B1 (ko) | 1994-02-14 | 2003-09-19 | 리엑스 유니버시타이트 라이덴 | 활성화된단백질c에대한약한항응고반응및/또는혈전증과관련된유전자결함의존재를검색하는방법 |
US5705395A (en) * | 1994-11-14 | 1998-01-06 | The Scripps Research Institute | Method for diagnosis of thrombotic disorders |
US5885971A (en) * | 1995-03-24 | 1999-03-23 | The Regents Of The University Of California | Gene therapy by secretory gland expression |
US6531455B1 (en) * | 1995-03-24 | 2003-03-11 | The Regents Of The University Of California | Delivery of polynucleotides by secretory gland expression |
US5874256A (en) * | 1995-06-06 | 1999-02-23 | Rijks Universiteit Leiden | Method for diagnosing an increased risk for thrombosis or a genetic defect causing thrombosis and kit for use with the same |
GB9604267D0 (en) * | 1996-02-29 | 1996-05-01 | Royal Infirmary Of Edinburgh N | Mutation assay |
ES2162361T3 (es) | 1998-03-19 | 2001-12-16 | Instrumentation Lab Spa | Metodos, kits y reactivos mejorados para el muestreo de defectos de la coagulacion sanguinea. |
DE19858278A1 (de) * | 1998-12-17 | 2000-06-21 | Dade Behring Marburg Gmbh | Verfahren zum Lokalisieren von Defekten im Gerinnungssystem |
JP4676585B2 (ja) * | 1999-12-24 | 2011-04-27 | 一般財団法人化学及血清療法研究所 | 血液凝固異常に基づく疾患の治療・予防用医薬組成物 |
US8914114B2 (en) | 2000-05-23 | 2014-12-16 | The Feinstein Institute For Medical Research | Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation |
US7615622B2 (en) * | 2001-01-12 | 2009-11-10 | University Of Maryland, Baltimore | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
WO2003039584A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and factor v polypeptides |
US7125846B2 (en) * | 2001-11-09 | 2006-10-24 | Novo Nordisk Healthcare A/G | Pharmaceutical composition comprising factor VII polypeptides and factor V polypeptides |
US7375100B2 (en) | 2003-06-04 | 2008-05-20 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7067541B2 (en) | 2003-06-04 | 2006-06-27 | Pfizer Inc | 2-amino-pyridine derivatives useful for the treatment of diseases |
US7211559B2 (en) * | 2003-10-31 | 2007-05-01 | University Of Maryland, Baltimore | Factor VIII compositions and methods |
US10912712B2 (en) | 2004-03-25 | 2021-02-09 | The Feinstein Institutes For Medical Research | Treatment of bleeding by non-invasive stimulation |
WO2005092308A2 (en) | 2004-03-25 | 2005-10-06 | The Feinstein Institute For Medical Research | Neural tourniquet |
WO2006027111A1 (en) * | 2004-09-06 | 2006-03-16 | Zlb Behring Gmbh | Modified coagulation factor viii with enhanced stability |
EP1833559B1 (en) | 2004-12-27 | 2010-11-24 | The Feinstein Institute for Medical Research | Treating inflammatory disorders by electrical vagus nerve stimulation |
US11207518B2 (en) | 2004-12-27 | 2021-12-28 | The Feinstein Institutes For Medical Research | Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway |
ATE510545T1 (de) | 2005-11-09 | 2011-06-15 | Alnylam Pharmaceuticals Inc | Zusammensetzungen und verfahren zur hemmung der expression von faktor v leiden mutationsgen |
WO2008059009A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Factor v mutants for hemostasis in hemophilia |
EP2081589B1 (en) * | 2006-11-16 | 2010-10-06 | Crucell Holland B.V. | Complementation of factor xi deficiency by factor v mutants |
WO2008059043A2 (en) * | 2006-11-16 | 2008-05-22 | Crucell Holland B.V. | Combination of coagulation factor viii with apc-resistant factor v |
WO2009029614A1 (en) | 2007-08-27 | 2009-03-05 | The Feinstein Institute For Medical Research | Devices and methods for inhibiting granulocyte activation by neural stimulation |
CN101969984A (zh) * | 2007-12-20 | 2011-02-09 | 昆士兰大学 | 调节止血的组合物及其用途 |
US9662490B2 (en) | 2008-03-31 | 2017-05-30 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug |
WO2009146030A1 (en) | 2008-03-31 | 2009-12-03 | The Feinstein Institute For Medical Research | Methods and systems for reducing inflammation by neuromodulation of t-cell activity |
AU2009316801C1 (en) | 2008-11-18 | 2015-12-24 | Setpoint Medical Corporation | Devices and methods for optimizing electrode placement for anti-inflammatory stimulation |
US9211410B2 (en) | 2009-05-01 | 2015-12-15 | Setpoint Medical Corporation | Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation |
US8996116B2 (en) | 2009-10-30 | 2015-03-31 | Setpoint Medical Corporation | Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction |
AU2010258792B2 (en) | 2009-06-09 | 2015-07-02 | Setpoint Medical Corporation | Nerve cuff with pocket for leadless stimulator |
US9833621B2 (en) | 2011-09-23 | 2017-12-05 | Setpoint Medical Corporation | Modulation of sirtuins by vagus nerve stimulation |
WO2014169145A1 (en) | 2013-04-10 | 2014-10-16 | Setpoint Medical Corporation | Closed-loop vagus nerve stimulation |
EP2515996B1 (en) | 2009-12-23 | 2019-09-18 | Setpoint Medical Corporation | Neural stimulation devices and systems for treatment of chronic inflammation |
ITFI20110084A1 (it) | 2011-04-22 | 2012-10-23 | Kedrion Spa | Nuovo processo per la preparazione di un concentrato di fv virus inattivato a partire da plasma umano, scalabile a livello industriale. |
CN103619405B (zh) | 2011-05-09 | 2015-11-25 | 赛博恩特医疗器械公司 | 用于治疗慢性炎症的胆碱能抗炎通路的单个脉冲激活 |
US9572983B2 (en) | 2012-03-26 | 2017-02-21 | Setpoint Medical Corporation | Devices and methods for modulation of bone erosion |
US11311725B2 (en) | 2014-10-24 | 2022-04-26 | Setpoint Medical Corporation | Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation |
US11406833B2 (en) | 2015-02-03 | 2022-08-09 | Setpoint Medical Corporation | Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator |
US10596367B2 (en) | 2016-01-13 | 2020-03-24 | Setpoint Medical Corporation | Systems and methods for establishing a nerve block |
US10695569B2 (en) | 2016-01-20 | 2020-06-30 | Setpoint Medical Corporation | Control of vagal stimulation |
WO2017127758A1 (en) | 2016-01-20 | 2017-07-27 | Setpoint Medical Corporation | Implantable microstimulators and inductive charging systems |
US11471681B2 (en) | 2016-01-20 | 2022-10-18 | Setpoint Medical Corporation | Batteryless implantable microstimulators |
US10583304B2 (en) | 2016-01-25 | 2020-03-10 | Setpoint Medical Corporation | Implantable neurostimulator having power control and thermal regulation and methods of use |
WO2019036470A1 (en) | 2017-08-14 | 2019-02-21 | Setpoint Medical Corporation | TESTING TEST FOR STIMULATION OF NERVE WAVE |
US11260229B2 (en) | 2018-09-25 | 2022-03-01 | The Feinstein Institutes For Medical Research | Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation |
IL298193B2 (en) | 2020-05-21 | 2024-01-01 | Feinstein Institutes For Medical Research | Systems and methods for stimulating the vagus nerve |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5451521A (en) * | 1986-05-29 | 1995-09-19 | Genetics Institute, Inc. | Procoagulant proteins |
-
1995
- 1995-04-21 US US08/722,240 patent/US6083905A/en not_active Expired - Fee Related
- 1995-04-21 DE DE69520569T patent/DE69520569T2/de not_active Expired - Lifetime
- 1995-04-21 AT AT95916845T patent/ATE200225T1/de not_active IP Right Cessation
- 1995-04-21 DK DK95916845T patent/DK0756638T3/da active
- 1995-04-21 ES ES95916845T patent/ES2157326T3/es not_active Expired - Lifetime
- 1995-04-21 AU AU23194/95A patent/AU697205B2/en not_active Ceased
- 1995-04-21 JP JP52755095A patent/JP3810080B2/ja not_active Expired - Fee Related
- 1995-04-21 CA CA002188463A patent/CA2188463C/en not_active Expired - Fee Related
- 1995-04-21 EP EP95916845A patent/EP0756638B1/en not_active Expired - Lifetime
- 1995-04-21 WO PCT/NL1995/000149 patent/WO1995029259A1/en active IP Right Grant
-
2001
- 2001-06-06 GR GR20010400853T patent/GR3036000T3/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU697205B2 (en) | 1998-10-01 |
DE69520569T2 (de) | 2001-10-04 |
EP0756638A1 (en) | 1997-02-05 |
JPH09512425A (ja) | 1997-12-16 |
DK0756638T3 (da) | 2001-07-23 |
AU2319495A (en) | 1995-11-16 |
CA2188463C (en) | 2007-12-11 |
ATE200225T1 (de) | 2001-04-15 |
CA2188463A1 (en) | 1995-11-02 |
JP3810080B2 (ja) | 2006-08-16 |
GR3036000T3 (en) | 2001-09-28 |
WO1995029259A1 (en) | 1995-11-02 |
US6083905A (en) | 2000-07-04 |
EP0756638B1 (en) | 2001-04-04 |
DE69520569D1 (de) | 2001-05-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2157326T3 (es) | Sistema para el tratamiento de anomalias en la cascada de coagulacion sanguinea. | |
EA200200755A1 (ru) | Опосредованная рецептором nogo блокада роста аксонов | |
CY1113145T1 (el) | Μορια υποδοχεα θυμικης στρωματικης λεμφοποιητινης και χρησεις αυτων | |
NO20010446L (no) | Substituert anilidforbindelser og metoder | |
ATE313802T1 (de) | Bestimmung von adrenomedullin-bindenden proteinen | |
DE69938183D1 (de) | Verwendungen eines borreliaziden epitops des aussermembranproteins c von borrelia burgdorferi (ospc) als impstoff | |
DE69033511T2 (de) | Verfahren zum Nachweis von Knochen- und anderen Bindegewebeerkrankungen in Menschen und Tieren | |
BR9906926A (pt) | Composições e métodos para tratamento de células tendo dna de minuto duplo | |
WO1999051186A3 (en) | Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders | |
MXPA05011085A (es) | Composiciones y metodos relacionados a stop-1. | |
DE60024997D1 (de) | Vgf polypeptide und verfahren zur behandlung von vgf-erkrankungen | |
AU2579995A (en) | Alpha b crystallin for use in diagnosis and therapy of auto-immune diseases in particular multiple sclerosis | |
ATE291621T1 (de) | Nukleinsaeuren und proteine der katze fc-epsilon rezeptor alpha-kette und deren verwendungen | |
AU2904197A (en) | Diagnostic method and apparatus based on polymorphism in an IL-6 gene | |
WO2003028536A3 (en) | Methods for diagnosing and treating heart disease | |
Kumar et al. | Biomedical Potentials of Protein Z: An Insight | |
WO2003025197A3 (en) | Mutant sh3-binding protein compositions and methods | |
DE60224778D1 (de) | Zusammensetzungen und Verfahren zur Behandlung und zur Detektion von proliferativen Störungen die mit der Überexpression des menschlichen "Transketolase like-1" gens in Zusammenhang stehen | |
Filipec et al. | Immunosuppressive effect of bovine seminal ribonuclease on a model of corneal transplantation in rabbit | |
DE69635989D1 (de) | Diagnostischer test für von pferdearthritisvirus verursachte krankheiten | |
COMPTON | Programmed cell death in avian thymocytes: role of the apoptotic endonuclease | |
DE19518931C1 (de) | Nukleinsäure mit einem polymorphen Bereich eines B¶2¶-Bradykinin-Rezeptor-Gens | |
MXPA03010739A (es) | Moleculas de marcador endotelial tumoral 7-alfa y uso de las mismas. | |
Baluch | A STUDY OF THE MOLECULAR EVENTS THAT OCCUR DURING INDUCTION OF PROPHAGE LAMBDA. | |
McCarthy et al. | Hyperparathyroidism, osteomalacia and peripheral neuropathy in a patient on anticonvulsant therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG2A | Definitive protection |
Ref document number: 756638 Country of ref document: ES |